Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $235.4 million.

  • Apellis Pharmaceuticals' Operating Expenses fell 357.01% to $235.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $936.0 million, marking a year-over-year decrease of 27.23%. This contributed to the annual value of $946.3 million for FY2024, which is 357.16% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Operating Expenses of $235.4 million as of Q3 2025, which was down 357.01% from $211.8 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Operating Expenses' 5-year high stood at $250.1 million during Q1 2025, with a 5-year trough of $124.6 million in Q1 2021.
  • Over the past 5 years, Apellis Pharmaceuticals' median Operating Expenses value was $215.4 million (recorded in 2023), while the average stood at $201.6 million.
  • In the last 5 years, Apellis Pharmaceuticals' Operating Expenses skyrocketed by 6874.16% in 2021 and then plummeted by 1537.32% in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' Operating Expenses (Quarter) stood at $149.7 million in 2021, then rose by 24.73% to $186.7 million in 2022, then increased by 23.66% to $230.9 million in 2023, then rose by 3.38% to $238.7 million in 2024, then decreased by 1.38% to $235.4 million in 2025.
  • Its Operating Expenses was $235.4 million in Q3 2025, compared to $211.8 million in Q2 2025 and $250.1 million in Q1 2025.